[1] Matsha T,Erasmus R,Kafuko A B,et al.Human papillomavirus associated with oesophageal cancer.J Clin Pathol,2002,55:587~590
[2] Zur Hausen H.Papillomaviruses and cancer: from basic studies to clinical application.Nat Rev Cancer,2002,2:342~350
[3] Baez A,Almodovar J I,Cantor A,et al.High frequency of HPV16associated head and neck squamous cell carcinoma in the Puerto Rican population.Head Neck,2004,26:778~784
[4] Wu Q J,Guo M,Lu Z M,et al.Detection of human papillomavirus16 in ovarian malignancy.Br J Cancer,2003,89:672~675
[5] Shehata B M,Otto K J,Sobol S E,et al.E6 and E7 oncogene expression by human papilloma virus (HPV) and the aggressive behavior of recurrent laryngeal papillomatosis (RLP).Pediatr Dev Pathol,2008,11:118~121
[6] Yan J,Reichenbach D K,Corbitt N,et al.Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.Vaccine,2009,27:431~440
[7] Nindl I,Rindfleisch K,Lotz B,et al.Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology,cervical intraepithelial neoplasia and cervical cancer.Int J Cancer,1999,82:203~207
[8] Roden R B,Ling M,Wu T C.Vaccination to prevent and treat cervical cancer.Hum Pathol,2004,35:971~982
[9] Cheng W F,Hung C H,Chai C Y,et al.Enhancement of sindbis virus selfreplicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen.J Virol,2001,75:2368~2376
[10] Oliveira S C,Harms J S,Afonso R R,et al.A genetic immunization adjuvant system based on BVP22antigen fusion.Hum Gene Ther,2001,12:1353~1359
[11] Qian X,Lu Y,Liu Q,et al.Prophylactic,therapeutic and antimetastatic effects of an HPV16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.Immunol Lett,2006,102:191~201
[12] Franceschi S.The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.Recent Results Cancer Res,2005,166:277~297
[13] Villa L L.Overview of the clinical development and results of a quadrivalent HPV (types 6,11,16,18) vaccine.Int J Infect Dis,2007,11 Suppl 2:S17~25
[14] Vambutas A,DeVoti J,Nouri M,et al.Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virusinduced lesions and latently infected sites in a preclinical cottontail rabbit papillomavirus model.Vaccine,2005,23:5271~5280
[15] Ohlschlager P,Pes M,Osen W,et al.An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV16 E7SH) induces an E7 wildtypespecific T cell response.Vaccine,2006,24:2880~2893
[16] Brinkman J A,Xu X,Kast W M.The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV16 induced tumors.Vaccine,2007,25:3437~3444
[17] Mouzakitis G,McLauchlan J,Barreca C,et al.Characterization of VP22 in herpes simplex virusinfected cells.J Virol,2005,79:12185~12198
[18] Duffy C,Mbong E F,Baines J D.VP22 of herpes simplex virus 1 promotes protein synthesis at late times in infection and accumulation of a subset of viral mRNAs at early times in infection.J Virol,2009,83:1009~1017
[19] Schwarze S R,Hruska K A,Dowdy S F.Protein transduction: unrestricted delivery into all cells? Trends Cell Biol,2000,10:290~295
[20] Bennett R P,Dalby B,Guy P M.Protein delivery using VP22.Nat Biotechnol,2002,20:20 |